newsfilter
← Latest News
GlobeNewswire·

LianBio Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Completed enrollment in China Phase 3 trial of mavacamten; topline data expected mid-2023 Submitted mavacamten New Drug Application (NDA) in Singapore Submitted infigratinib NDA in Hong Kong Three additional registration-enabling programs to begi